Further to its letter dated May 17, 2024 and pursuant to Regulation 33 and 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Bilcare has informed that it enclosed the following: A. Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31 March 2024, duly approved by the Board of Directors at its meeting held on 27th May 2024. B. Auditor's Report (Standalone and Consolidated) of the Auditors on the Audited Financial Results for the year ended 31 March 2024. C. Declaration duly signed by Managing Director of the Company pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016. D. Board of Directors has not recommended any dividend for the year ended 31 March 2024. Further, it has informed that during the year, the Company incorporated a wholly owned subsidiary ‘Bilcare Pharma Solutions Limited’. The meeting of the Board of Directors commenced at 2.30 pm and concluded at 11.30 pm.
The above information is a part of company’s filings submitted to BSE.
